When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

What happened with Novo Nordisk stock? On Dec. 20, Novo announced results from a phase 3 clinical trial surrounding one of ...

Stay updated on the latest developments in the GLP-1 drug class, including a new generic entering the market, weight loss results, FDA decisions & cost issues.

So is Ozempic safe? Novo Nordisk, the pharmaceutical company that makes Ozempic and Wegovy, stands behind the safety and efficacy of all its GLP-1 medicines when they’re used as indicated and ...

Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk 's ( NVO 0.15%) stock crashed ...

The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide ...

Novo Nordisk’s GLP-1 agonist Ozempic has shown efficacy in yet another indication, achieving a 24% reduction in kidney disease-related events in people with type 2 diabetes and chronic kidney ...

Novo Nordisk (NYSE:NVO) has secured approval from the European Medicines Agency (EMA) for a kidney disease-related label expansion for its blockbuster drug Ozempic (semaglutide) in Europe, on December ...

Ozempic maker Novo Nordisk saw its value fall by as much as £82billion yesterday after a weight loss drug trial fell short of expectations. It was one of the Danish pharma giant's worst days on ...

Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes, drugmakers Novo Nordisk and Eli Lilly have been battling to leapfrog each other with newer and more effective ...

According to its website, Novo Nordisk was founded in 1923 in Copenhagen, Denmark’s capital city. It is best known for manufacturing diabetes medications, including Ozempic and Wegovy.

Shares in Novo Nordisk have fallen by more than a quarter after the Ozempic maker revealed a set ... bond yields have surged higher - with 30-year gilt coupons close to their highest level since ...